Dr. Ahmed E. Ghazi

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

Dr. Christian Pavlovich is Bernard L. Schwartz Distinguished Professor in Urologic Oncology at the Johns Hopkins University School of Medicine and Director of the Prostate Cancer Active Surveillance Program at the Brady Urological Institute. Dr. Pavlovich treats cancer with an emphasis on minimizing morbidity and maximizing quality of life while offering patients the latest treatment options and techniques. His clinical focus is on prostate and kidney cancer, and on clinical trials regarding detection, surveillance, and immunotherapy. With more than 20 years of experience with minimally-invasive surgery for the treatment of urologic cancers, he is expert in robotic surgery and was named one of the top prostate cancer surgeons in the United States by Newsweek in 2024. In addition, he offers patients modern diagnostic biopsy techniques, and for prostate cancer patients active surveillance and ablative options including cryotherapy and TULSA. Dr. Pavlovich grew up in Washington DC, went to Harvard University, and then earned his medical degree at the University of California, San Francisco (UCSF) School of Medicine. He then completed a urology residency at New York Hospital-Cornell Medical Center and a National Cancer Institute SUO fellowship in urologic oncology before joining the Hopkins faculty in 2001. Dr. Pavlovich has published over 150 peer-reviewed articles, is Associate Editor of The Prostate and is on the Editorial Board of the British Journal of Urology International. He was the inaugural Director of the Brady Urological Institute’s SUO Urologic Oncology Fellowship (2014 -2024) and is the recipient of three “best teaching/research mentor” awards from the Urology residents at Johns Hopkins. Dr. Pavlovich speaks English, French, Spanish, German, and Serbo-Croatian. He enjoys spending time with his wife and children, following their pursuits, and skiing, diving, running, wildlife, and the great outdoors. Dr. Pavlovich is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Dr. Channing J. Paller is a medical oncologist at Sibley Memorial Hospital and a professor of oncology at the Johns Hopkins University School of Medicine. She practices out of the Prostate Cancer Multidisciplinary Clinic at Sibley Memorial Hospital in Washington, D.C., and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD. Dr. Paller has expertise in prostate, bladder, kidney, and testicular cancer. Dr. Paller earned her medical degree from Harvard Medical School and completed a residency in internal medicine, followed by a fellowship in hematology and oncology at Johns Hopkins University School of Medicine. In addition, Dr. Paller completed a rotation with the chief of the Investigational Drug Branch at the National Cancer Institute (NCI) Cancer Therapy Evaluation Program and a rotation with the associate director for regulatory science in the Office of Oncology Drug Products at the Food and Drug Administration. She also completed rotations at the Weizmann Institute of Israel’s Department of Biological Regulation and McCord Hospital in South Africa, where she participated in the Harvard AIDS project. In 2016, Dr. Paller was one of only five oncologists awarded the NCI Mentored Patient-Oriented Research Career Development Award. In 2015, she received the 2015 Passano Clinician Scientist Award for early-stage research that is already making a contribution to science. Earlier in her career, she was selected for both a 2011-2012 Young Investigator Award by the American Society of Clinical Oncology and for the 2011-12 Eastern Cooperative Oncology Group Paul Carbone Award. Dr. Paller is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Paller’s research focuses on evaluating new therapies for prostate cancer, particularly combination therapies that engage the immune system. She is the principal investigator on two multi-site clinical trials and was the first author on the NCI Investigational Drug Steering Committee publication, “Consensus Recommendations on the Phase I Combination Clinical Trials of the Clinical Trial Design Task Force.” Dr. Paller was the chair for the oral abstract session on genitourinary cancer at the 2015 Annual Meeting of the American Society of Clinical Oncology and she is currently funded by an NCI immunotherapy grant to look at combination therapies that link standard of care therapy with inhibition of transforming growth factor beta in prostate cancer. She is also opening trials of vitamin C with chemotherapy in prostate cancer and of mistletoe in all solid tumors. Dr. Paller is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Hormone Replacement Therapy (HRT), and Prostatectomy.